NCT04893512View on ClinicalTrials.gov

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
SARS-CoV-2 (COVID-19)
Interventions
DRUG

Orally Suspension of CoV2-OGEN1

CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug

Trial Locations (1)

1010

Auckland Clinical Studies Ltd (NZCR OpCo Limited), Grafton

Sponsors

Lead Sponsor

Syneos Health
All Listed Sponsors
collaborator

US Specialty Formulations, LLC

UNKNOWN

lead

Syneos Health

OTHER